Dockendorff and MacMillan are slated to replace Uwe Reinhardt and Bruce Byrnes, will not stand for re-election at Boston Scientific’s annual shareholders meeting in May, the company said.
Dockendorff, the longtime finance chief at Covidien until its $50 billion acquisition by Medtronic in January, is also on the board at Haemonetics and Keysight Technologies, according to a press release. MacMillan led Stryker until his ouster in 2012; he took the helm at Hologic (NSDQ:HOLX) in December 2013. He’s also on the board at Alere (NYSE:ALR), according to the release.
"We are thankful for the guidance and years of dedicated service that Dr. Reinhardt and Mr. Byrnes contributed to Boston Scientific, and we are pleased to welcome Mr. Dockendorff and Mr. MacMillan to our board," Boston Scientific chairman Pete Nicholas said in prepared remarks. "Their extensive experience and management insights will be valuable additions as we continue to deliver meaningful innovation to address the unmet needs of patients around the world."
Breg promotes president Lee to CEO
Breg Inc. said it promoted president Brad Lee to CEO. Breg, the former sports medicine segment of Orthofix (NSDQ:OFIX), was acquired for $158 million in cash by private equity firm Water Street Healthcare Partners in 2012.
Penumbra grabs J.P. Morgan’s Kosaraju for CFO
Penumbra Inc. said it named Sri Kosaraju, the former head of healthcare at J.P. Morgan, to be its new chief financial officer and head of strategy.
SynCardia names Hudspeth CFO
SynCardia said it named Dan Hudspeth to be its new CFO, touting his leadership in a trio of public offerings and more than 30 private equity and debt financings.
Ex-Patient Safety Technologies CFO is new finance chief at Biolase
Biolase (NSDQ:BIOL) looked to the former finance chief for Patient Safety Technologies (OTC:PSTX), which was acquired by Stryker last year, to be its new CFO. David Dreyer replaces Frederick Furry, who resigned Jan. 31 "to pursue other opportunities."